Viewing Protocol Section

Home Icon Home Search Icon Search Alerts Icon Stocks Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs eRecord Icon eRecord
Main Search All Studies All Organizations Report Bug
Viewing Protocol Section

Thank You for evaluating our software.

Clinical Trials

To give you an idea of how we make custom software. We have taken all of the Clinical Trials Information from our Federal Government(https://clinicaltrials.gov/).

The JSON File Structure of the files is as follows: Full Study -> Study => Sections => Modules. You are currently viewing a Protocol Section and its Modules.

We give the table structure here to give you an idea of what you are looking at. We put the explanation to the left and the data to the right.

A Protocol Section has the following Modules.

1. Identification Module

2. Status Module

3. Sponsor Collaborators Module

4. Oversight Module

5. Description Module

6. Conditions Module

7. Design Module

8. Arms Interventions Module

9. Outcomes Module

10. Eligibility Module

11. Contacts Locations Module

12. References Module

13. IPD Sharing Statement Module

Viewing Protocol Section

Study NCT00134667
Ignite Creation Date: 2024-05-05 @ 11:47 AM
Last Modification Date: 2024-10-26 @ 9:13 AM
Study NCT ID: NCT00134667
Protocol Section: NCT00134667
Start Identification Module Data
Expand Identification Module Data
Brief Title: Macugen Pegaptanib Sodium Alone Versus Macugen in Combination With PDT Photodynamic Therapy With Visudyne Verteporfin in Patients With Age-Related Macular Degeneration AMD
Official Title: A Phase IIIbIV Randomized Double-Masked Active Controlled Dose-Ranging Multi-Center Comparative Trial in Parallel Groups to Compare the Safety and Efficacy of Intravitreal Injections of Pegaptanib Sodium Macugen Given Every 6 Weeks for 102 Weeks to Pegaptanib Sodium Plus Photodynamic Therapy PDT With Visudyne in Patients With Exudative Age-Related Macular Degeneration AMD
Acronym: None
Organization: Eyetech Pharmaceuticals
Organization Class: INDUSTRY
Organization Study ID: EOP1012
Start Status Module Data
Status Verified Date: 2007-01
Overall Status: TERMINATED
Study First Submit Date:
Study First Submit QC Date:
Last Update Submit Date:
Status:
Start Sponsor Collaborators Module Data
Investigator:
Lead Sponsor: Eyetech Pharmaceuticals
Lead Sponsor Class: INDUSTRY
Lead Sponsor: Eyetech Pharmaceuticals
Start Oversight Module Data
Description Module:
Study Last Update Post Date Type(Status Module):
Attachment: Upload